Summary of highlights for you to draw conclusions:
-Mortality (outcomes endpoints changed) so VEST becomes events trial (yep. a defib works!)
-GE pulls out of analytics, MDT pulls out as well.
-PI's have concerns of selection bias altering the results (cherry picking of patients) and over involvement by Zoll in enrollment process. The early mortality benefit "separation of the curves" is now more inline with the control group. Outcomes benefit reported to be 0.8.
-Quality of Life assessment as reported directly by JW at an investigator meeting in 2012 showed that patients actually did worse in vest than in control group as related to medical adherence/core measure and mental health/well-being. Routine calls for follow-up to Vest patients addressing QOL questions was dropped. I guess you can't report what isn't measured.
-Site attrition is beneficial to Zoll not the integrity (?) of the study results. They string along for various reasons so as not to actually have to report data. Think in comparison to your comp plan (hire, enroll, wash, reset, hire, enroll, wash, reset): sales=(hire, wash, fire, reset).